Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Welcome to a special feature by Oncology Frontier, where we bridge the gap between continents in the realm of medical innovation. Today, we're honored to host Marie-Pier St-Laurent from the University of British Columbia. As part of our exclusive Specialist Interview series, Marie-Pier will be sharing valuable insights from her recent abstract presented at ASCO GU. Stay tuned as we delve into groundbreaking research that's shaping the future of oncological care. Visit us at www.ioncol.com for more thought-provoking content
Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology Department at Shanxi Baiqiu'en Hospital, China, had three research results selected for presentation. Oncology Frontier specially invited Dr. Wei to present the findings.
Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes

Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes

Dr. Komrokji delved into the revised classifications for Myelodysplastic Syndromes (MDS) unveiled at the International Congress. The discussion contrasted the 2016 and 2022 editions, spotlighting new molecularly defined subcategories, such as SF3B1 MDS and biallelic p53, alongside morphological distinctions like MDS with increased blast types, hypoplastic MDS, and MDS with fibrosis. Dr. Komrokji's insights underscored the evolving MDS classification landscape and promising therapeutic frontiers, marking a pivotal advancement in understanding MDS and refining patient care.
Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia

Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia

Abstract: Dr. Nigel Russell provides insights into the recent developments in the treatment landscape of Acute Myeloid Leukemia (AML). The discussion encompasses the combination of FLT3 mutation inhibitors with intensive chemotherapy, emphasizing the effectiveness and safety demonstrated by the combination of midostaurin with gemtuzumab ozogamicin. The presentation explores emerging FLT3 inhibitors like quizartinib and their potential in combination with chemotherapy. Additionally, Dr. Russell delves into a groundbreaking study involving the combination of the FLAG-Ida regimen with gemtuzumab ozogamicin for patients with NPM1-mutated AML. The study reveals significantly improved event-free and overall survival, indicating a promising therapeutic approach for this patient subgroup. Furthermore, the discussion touches upon the advancements in bispecific antibodies in AML, particularly focusing on blinatumomab's role in targeting CD19 for patients with relapsed core-binding factor leukemia. The potential use of bispecific antibodies in eradicating minimal residual disease after intensive therapy is highlighted, offering a glimpse into a targeted therapeutic strategy for AML patients. Overall, these insights contribute to the evolving landscape of AML treatment, showcasing promising avenues for improving patient outcomes.
Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

Editor's Note: In this captivating interview, Dr. Niels Van de Donk offers an extensive exploration of the recent advancements and future prospects in Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory multiple myeloma (RRMM). Dr. Donk's insights, ranging from the dynamic landscape of CAR-T targets to pivotal studies like MAJESTEC-1, provide a comprehensive overview of the current status, challenges, and promising directions in the ever-evolving field of RRMM treatment.01 Oncology Frontier: Unpacking the Current Progress in CAR-T Targets for RRMM
Dr. Nicholas Short: The Latest Therapeutic Advances in Acute Lymphoblastic Leukemia

Dr. Nicholas Short: The Latest Therapeutic Advances in Acute Lymphoblastic Leukemia

Abstract: Dr. Nicholas Short delves into the forefront of advancements in the treatment of Acute Lymphoblastic Leukemia (ALL) at the EHA Congress 2023. He discusses the evolution of therapeutic strategies, particularly in B cell ALL, where various agents like blinatumomab, inotuzumab ozogamicin, and CD19 CAR T cell products have demonstrated notable efficacy. Notably, the focus on Philadelphia Chromosome-positive ALL introduces potent tyrosine kinase inhibitors like ponatinib, exhibiting promising outcomes surpassing earlier treatments. Further, Dr. Short presents compelling insights into an ongoing study exploring a chemotherapy-free regimen using ponatinib and blinatumomab for newly diagnosed Ph-positive ALL patients. This regimen showcases high response rates and deep molecular responses, potentially redefining the standard of care without the necessity of transplantation in initial remission. Additionally, he emphasizes the emergence of CAR-T cell therapies targeting T cell ALL, addressing a longstanding therapeutic gap. These advances herald promising directions in the ALL landscape, presenting novel possibilities for improved treatment modalities.
Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma

Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma

Extranodal NK/T cell lymphoma (ENKTCL), nasal type, is a rare subtype prevalent in Asian populations and associated with the Epstein-Barr virus (EBV). Currently, patients' prognosis remains poor, especially for relapsed/refractory (R/R) cases. From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany. A selected oral presentation (Abstract No: S226) revealed significant efficacy in treating R/R ENKTCL patients with PD-1 inhibitors alone or in combination. This study once again confirms that immune checkpoint inhibitors have become a crucial therapeutic approach for R/R ENKTCL patients. Oncology Frontier had the privilege of inviting Dr. Huang Huiqiang from Sun Yat-sen University Cancer Center, China, to share the results and insights from this research at the conference.
Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

Editor's Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming's team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper insights into this study and its implications for the current status of ITP treatment, Oncology Frontier had an exclusive interview with Dr. Hou Ming. He provided a detailed overview of the current situation of ITP treatment in China and the promising future of using BTK inhibitors for ITP therapy.